Spots Global Cancer Trial Database for Safety and Tolerability of Intravenous Administration of ICVB-1042
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability of Intravenous Administration of ICVB-1042
Official Title: Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors
Study ID: NCT05904236
Conditions
Interventions
Study Description
Brief Summary: Study to evaluate the safety and tolerability of intravenous ICVB-1042
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Cancer Associates, San Marcos, California, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
NYU Langone Health, Perlmutter Cancer Center, New York, New York, United States
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Carolina BioOncology, Huntersville, North Carolina, United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Next Oncology, Dallas, Irving, Texas, United States
Next Oncology, San Antonio, San Antonio, Texas, United States
Next Oncology, Virginia, Fairfax, Virginia, United States
Contact Details
Name: Julie Maltzman, MD
Affiliation: IconOVir Bio
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
